Captura Biopharma
Captura is developing an orally administered MCM for radionuclide contamination.
Based in AR
AI Overview
With $66K in lobbying spend across 17 quarterly filings, Captura Biopharma is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2022 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2022 | $60K |
| 2023 | $6K |
| 2024 | $0 |
| 2025 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Captura Biopharma disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Defense, Health Issues, Disaster Planning
Support Captura Biopharma in educating executive and legislative branch officials and personnel on the current medical countermeasure limitations of existing radionuclide and heavy metal exposure medi
Response capabilities related to internal radionuclide contamination.
FY2024 NDAA; FY2024 Defense Appropriations
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.